Free Trial

Novartis (NVS) Stock Price, News & Analysis

Novartis logo
$117.62 +0.16 (+0.13%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$117.16 -0.46 (-0.39%)
As of 07/25/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Novartis Stock (NYSE:NVS)

Key Stats

Today's Range
$116.25
$117.71
50-Day Range
$110.71
$123.83
52-Week Range
$96.06
$124.83
Volume
2.46 million shs
Average Volume
1.86 million shs
Market Capitalization
$248.46 billion
P/E Ratio
17.12
Dividend Yield
2.21%
Price Target
$123.67
Consensus Rating
Hold

Company Overview

Novartis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

NVS MarketRank™: 

Novartis scored higher than 35% of companies evaluated by MarketBeat, and ranked 781st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novartis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Novartis has received no research coverage in the past 90 days.

  • Read more about Novartis' stock forecast and price target.
  • Earnings Growth

    Earnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novartis is 17.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.97.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novartis is 17.12, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.10.

  • Price to Earnings Growth Ratio

    Novartis has a PEG Ratio of 1.66. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novartis has a P/B Ratio of 5.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.21% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently increased by 4.91%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Novartis pays a meaningful dividend of 2.21%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novartis does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novartis is 37.85%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novartis will have a dividend payout ratio of 29.51% next year. This indicates that Novartis will be able to sustain or increase its dividend.

  • Read more about Novartis' dividend.
  • Percentage of Shares Shorted

    0.21% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently increased by 4.91%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Novartis has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Novartis this week, compared to 18 articles on an average week.
  • Search Interest

    11 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novartis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Novartis is held by insiders.

  • Percentage Held by Institutions

    Only 13.12% of the stock of Novartis is held by institutions.

  • Read more about Novartis' insider trading history.
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

Is this the biggest winner of Trump’s tariffs?
America’s industrial comeback is underway — and it’s bigger than anyone expected. Over $5 trillion has already been pledged to restore U.S. manufacturing. Trump’s tariffs and trade pressure have set off a massive reshoring push, and the flood of investment is still gaining steam. But while everyone’s watching the big names, one under-the-radar company holds the key tech that could make it all work — and potentially benefit the most.
Novartis AG (NYSE:NVS) Q2 2025 Earnings Call Transcript
See More Headlines

NVS Stock Analysis - Frequently Asked Questions

Novartis' stock was trading at $97.31 at the start of the year. Since then, NVS shares have increased by 20.9% and is now trading at $117.6170.

Novartis AG (NYSE:NVS) issued its earnings results on Thursday, July, 17th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. The company's revenue was up 12.3% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more.

Top institutional investors of Novartis include Scharf Investments LLC (0.06%), Truist Financial Corp (0.04%), Mirae Asset Global Investments Co. Ltd. (0.02%) and Janney Montgomery Scott LLC (0.01%).

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK).

Company Calendar

Last Earnings
7/17/2025
Today
7/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NVS
CIK
1114448
Employees
75,883
Year Founded
1996

Price Target and Rating

High Price Target
$130.00
Low Price Target
$120.00
Potential Upside/Downside
+5.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.87
Trailing P/E Ratio
17.12
Forward P/E Ratio
13.92
P/E Growth
1.66
Net Income
$11.94 billion
Net Margins
25.64%
Pretax Margin
29.30%
Return on Equity
41.08%
Return on Assets
16.83%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
0.82
Quick Ratio
0.62

Sales & Book Value

Annual Sales
$50.32 billion
Price / Sales
4.94
Cash Flow
$10.71 per share
Price / Cash Flow
10.98
Book Value
$19.91 per share
Price / Book
5.91

Miscellaneous

Outstanding Shares
2,112,420,000
Free Float
2,112,211,000
Market Cap
$248.46 billion
Optionable
Optionable
Beta
0.59

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NYSE:NVS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners